Esperion Therapeutics Inc (ESPR)

NASDAQ
Currency in USD
2.210
-0.050(-2.21%)
Closed
After Hours
2.2100.000(0.00%)
ESPR Scorecard
Full Analysis
Analysts anticipate sales growth in the current year
Fair Value
Day's Range
2.1702.310
52 wk Range
1.5803.940
Key Statistics
Edit
Prev. Close
2.26
Open
2.25
Day's Range
2.17-2.31
52 wk Range
1.58-3.94
Volume
2.55M
Average Volume (3m)
5.99M
1-Year Change
9.41%
Book Value / Share
-1.89
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ESPR Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
7.131
Upside
+222.68%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts do not anticipate the company will be profitable this year
Show more

Esperion Therapeutics Inc Company Profile

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company’s products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Employees
240

Compare ESPR to Peers and Sector

Metrics to compare
ESPR
Peers
Sector
Relationship
P/E Ratio
−5.0x−0.8x−0.6x
PEG Ratio
−0.07−0.010.00
Price/Book
−1.2x−0.1x2.6x
Price / LTM Sales
1.5x4.4x3.1x
Upside (Analyst Target)
194.1%208.9%53.6%
Fair Value Upside
Unlock1.7%8.0%Unlock

Analyst Ratings

6 Buy
2 Hold
1 Sell
Ratings:
9 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 7.131

(+222.68% Upside)

Earnings

Latest Release
Nov 07, 2024
EPS / Forecast
-0.15 / -0.1753
Revenue / Forecast
51.63M / 51.31M
EPS Revisions
Last 90 days

FAQ

What Is the Esperion (ESPR) Stock Price Today?

The Esperion stock price today is 2.21

What Stock Exchange Does Esperion Trade On?

Esperion is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for Esperion?

The stock symbol for Esperion is "ESPR."

What Is the Esperion Market Cap?

As of today, Esperion market cap is 435.45M.

What is Esperion Earnings Per Share?

The Esperion EPS is -0.521.

What Is the Next Esperion Earnings Date?

Esperion will release its next earnings report on 26 Feb 2025.

From a Technical Analysis Perspective, Is ESPR a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.